Dokeos

Dokeos is a learning management system (LMS) vendor founded in 2004, headquartered in Belgium with offices in Paris, Brussels, Boston, and Rabat. The company specializes in GxP-compliant training solutions for regulated industries, particularly pharmaceutical, biotechnology, healthcare, medical device, and manufacturing sectors.

The flagship product, Dokeos GxP LMS (xLms platform), delivers FDA 21 CFR Part 11 and EU Annex 11-compliant training management with validated system capabilities. Dokeos serves over 2 million users across 400+ clients globally, including pharmaceutical customers Alcon, Medtronic, IQVIA, Oxurion, Eli Lilly, Merck, and Ipsen.

Dokeos has supported 15+ FDA inspections with no major findings. The company brings 40 years of combined pharmaceutical experience to its platform development and customer support, positioning itself as a specialist in GxP-compliant learning management.

Lyvia Group acquired Dokeos on June 18, 2024 (announced August 6, 2024).

Dokeos specializes in regulated industries, with particular strength in pharmaceutical and biotechnology sectors. The GxP LMS is purpose-built for FDA 21 CFR Part 11 and EU Annex 11 compliance, positioning Dokeos as a pharma-focused LMS provider.

The company serves 400+ clients globally with over 2 million users, including pharmaceutical customers Alcon, Medtronic, IQVIA, Oxurion, Eli Lilly, Merck, and Ipsen. These customers span Big Pharma, contract research organizations (CROs), and medical device manufacturers.

Dokeos brings 40 years of combined pharmaceutical industry experience to its platform development and customer support teams. The company has supported 15+ FDA inspections with no major findings. The platform is ISO 13485 certified (medical device quality management standard).

Dokeos positions itself as a specialist in GxP-compliant training management, with product features designed for protocol training, investigator qualification, study documentation, and multi-site training coordination.

Revenue is undisclosed. Dokeos is privately held; the terms of its June 18, 2024 acquisition by Lyvia Group (announced August 6, 2024), including purchase price and valuation, are undisclosed.

Dokeos serves 400+ clients with over 2 million users globally on a cloud-based SaaS subscription model. Prior to the acquisition, Dokeos operated as an independent private company with no disclosed venture capital funding or public investment round.

Dokeos's product portfolio centers on its flagship Dokeos GxP LMS (xLms platform), a cloud-based learning management system built for regulated industries requiring FDA 21 CFR Part 11 and EU Annex 11 compliance.

The GxP LMS provides validated system capabilities: Computer System Validation (CSV) documentation, electronic signatures, and tamper-proof audit trails. The platform supports protocol training, investigator qualification, study documentation management, and multi-site training coordination.

Dokeos's strategy is focused on regulatory compliance features for pharmaceutical, biotechnology, medical device, and healthcare organizations. The xLms platform architecture is built from the ground up for GxP compliance.

The product strategy emphasizes regulatory reliability over feature breadth: validation documentation, FDA inspection readiness, and compliance reporting take precedence over features like gamification or social learning.

Specific technology partnerships and integration ecosystem details are undisclosed. The platform integrates with HR systems, quality management systems, and other enterprise applications; no named technology-alliance partner (such as Microsoft, SAP, Oracle, or Salesforce), cloud hosting partner, reseller, or implementation/consulting partner is disclosed.

No industry affiliation or membership in a pharmaceutical quality organization (such as ISPE, PDA, or PQG) is disclosed.

Dokeos provides implementation and validation support services, including Computer System Validation (CSV) documentation packages covering Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) protocols.

Professional services include system configuration, content migration from legacy training systems, user training for administrators and end users, and validation assistance. The team brings 40 years of combined pharmaceutical industry experience in GxP compliance, audit trail management, and electronic signature implementation.

Support availability details (24/7 coverage, regional support centers, language capabilities) are undisclosed. Dokeos has offices in Belgium, France, the United States, and Morocco, giving it a geographic presence across Europe and North America.

Customer success programs, user community forums, annual conferences, and certification programs are undisclosed.

Dokeos holds ISO 13485 certification (medical device quality management standard). The platform has supported 15+ FDA inspections with no major findings.

The company brings 40 years of combined pharmaceutical industry experience across its team; specific leadership backgrounds and credentials are undisclosed. Customers include Alcon, Medtronic, IQVIA, Eli Lilly, Merck, and Ipsen.

Analyst recognition from Gartner, Forrester, or industry-specific research firms is undisclosed. Awards and industry recognition are undisclosed.

Dokeos has roughly 30 employees. The website provides product information and customer references; content resources (whitepapers, webinars, case studies, demo videos) are limited. No high-profile social media engagement or frequent press release activity was found.

No changes to market presence following the 2024 acquisition by Lyvia Group have been publicly announced. Dokeos's market positioning emphasizes regulatory compliance, FDA inspection readiness, and pharmaceutical expertise over feature breadth or user experience innovation.

The website emphasizes compliance credentials and customer validation over consumer-oriented design aesthetics. The company's market visibility is primarily within pharmaceutical quality and compliance professional networks.